Omicron News and Research

RSS

Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

In a new study, researchers discovered human monoclonal antibodies, which were specific and potent against the severe acute respiratory syndrome coronavirus 2 Omicron variant.

23 Mar 2022

Natural infection versus messenger RNA vaccination-induced immune protection

Researchers compared the immune protection provided by naturally acquired COVID-19 and its vaccination in Qatar residents.

23 Mar 2022

Novel monoclonal antibody found to have substantial neutralizing capacity against SARS-CoV-2 Omicron variant

Researchers reported a new monoclonal antibody, P2G3, which significantly neutralized the SARS-CoV-2 Omicron variant.

23 Mar 2022

The significance of bedside lung ultrasound on predicting COVID-19-related hospitalization in children

A recent study demonstrated the significance of bedside lung ultrasound on predicting COVID-19-related hospitalization in children.

23 Mar 2022

New model suggests long-range transmission of SARS-CoV-2

A new study describes the long-range transmission of SARS-CoV-2 through aerosolized particles as a possibility.

22 Mar 2022

Novel nanoparticle-based COVID vaccines induce long-term neutralizing antibody response

Researchers report the results for a new SARS-CoV-2 vaccine currently in Phase III clinical trial known as I53-50.

22 Mar 2022

COVID booster vaccination more effective relative to 2-dose series

A booster dose of a mRNA-based COVID-19 vaccine is more effective than the two-dose primary vaccination regimen in preventing SARS-CoV-2 infections.

22 Mar 2022

The relative performance of OPS, NPS, and saliva for detecting the Delta and Omicron SARS-CoV-2 variants

Scientists have worked extensively hard to contain the COVID-19 pandemic caused by the rapid transmission of SARS-CoV-2.

22 Mar 2022

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Researchers have determined the effect of booster immunization on the levels of antibodies generated, against SARS-CoV-2 variants, including the Omicron strain, in cancer patients with or without active B cell-targeted therapy.

22 Mar 2022

Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor

Researchers presented a systematic analysis of the affinity and conformational dynamics between the binding of SARS-CoV-2 receptor-binding domain spike protein and the host angiotensin-converting enzyme 2 receptor.

22 Mar 2022

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Researchers discussed patient features, treatment-associated process measures, and outcomes associated with early monoclonal antibody and antiviral therapy in high-risk pediatric patients infected with the SARS-CoV-2 Omicron variant.

22 Mar 2022

Length of stay distributions of hospitalized COVID-19 cases during a mixed Omicron-Delta epidemic in Australia

Researchers determined the hospital stay lengths for COVID-19 patients infected by the Omicron and Delta variants of SARS-CoV-2.

22 Mar 2022

Posaconazole found to be effective as a small molecule fusion inhibitor against SARS-CoV-2 variants

Researchers evaluated the importance of the Ex3Lx6L motif in SARS-CoV-2 entry into host cells mediated by the spike protein syncytium formation and membrane fusion.

22 Mar 2022

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

22 Mar 2022

SARS-CoV-2 infection risk among dialysis patients during Omicron surge

A recent study posted to the medRxiv* preprint server evaluated the antibody responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) patients receiving hemodialysis.

22 Mar 2022

Is COVID-19 on the verge of ending?

Researchers explore the changes arising in SARS-CoV-2 over time.

21 Mar 2022

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

Researchers demonstrate the broad neutralization potential of a strategically engineered circRNA using mice as a model system.

21 Mar 2022

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

The immune system deteriorates with age, making COVID-19 particularly deadly in older people - but to date, no clinically available medication addresses this key risk factor.

21 Mar 2022

Clinical severity of SARS-CoV-2-Omicron infection found to be lower than Delta infection

Researchers evaluated the severity of SARS-CoV-2cc infection by the Omicron variant compared to the Delta variant.

21 Mar 2022

Phase 2 trial evaluates the safety and immunogenicity of two doses of the SARS-CoV-2 vaccine MVC-COV1901 in adolescents

A recent study evaluated the safety and immunogenicity of a COVID-19 vaccine in a phase II trial.

21 Mar 2022

Omicron News and Research

Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

Natural infection versus messenger RNA vaccination-induced immune protection

Novel monoclonal antibody found to have substantial neutralizing capacity against SARS-CoV-2 Omicron variant

The significance of bedside lung ultrasound on predicting COVID-19-related hospitalization in children

New model suggests long-range transmission of SARS-CoV-2

Novel nanoparticle-based COVID vaccines induce long-term neutralizing antibody response

COVID booster vaccination more effective relative to 2-dose series

The relative performance of OPS, NPS, and saliva for detecting the Delta and Omicron SARS-CoV-2 variants

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Molecular dynamic simulations unveil conformational dynamics of SARS-CoV-2 spike protein RBD and ACE2 receptor

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Length of stay distributions of hospitalized COVID-19 cases during a mixed Omicron-Delta epidemic in Australia

Posaconazole found to be effective as a small molecule fusion inhibitor against SARS-CoV-2 variants

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

SARS-CoV-2 infection risk among dialysis patients during Omicron surge

Is COVID-19 on the verge of ending?

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

Clinical severity of SARS-CoV-2-Omicron infection found to be lower than Delta infection

Phase 2 trial evaluates the safety and immunogenicity of two doses of the SARS-CoV-2 vaccine MVC-COV1901 in adolescents

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News